研究と業績　2019年

研究と業績　2019年

英文

  1. Matsumoto Y, Sawa K, Fukui M, Oyanagi J, Izumi M, Ogawa K, Suzumura T, Watanabe T, Kaneda H, Mitsuoka S, Asai K, Kimura T, Yamamoto N, Koh Y, Kawaguchi T. Impact of tumor microenvironment on the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer. Cancer Sci 2019;110:3244-3254.
  2. Yamamoto N, Watanabe T, Yamada K, Nakai T, Suzumura T, Sakagami K, Yoshimoto N, Sato K, Tanaka H, Mitsuoka S, Asai K, Kimura T, Kanazawa H, Hirata K, Kawaguchi T. Efficacy and safety of ultrasound (US) guided percutaneous needle biopsy for peripheral lung or pleural lesion: comparison with computed tomography (CT) guided needle biopsy. J Thorac Dis 2019;11:936-943.
  3. Sugitani A, Asai K, Watanabe T, Suzumura T, Kojima K, Kubo H, Sato K, Ijiri N, Yamada K, Kimura T, Fukumoto S, Hirata K, Kawaguchi T. A polymorphism rs6726395 in Nrf2 contributes to the development of emphysema-associated age in smokers without COPD. Lung 2019;197:559-564.
  4. Naito M, Tamiya A, Takeda M, Taniguchi Y, Saijo N, Naoki Y, Okishio K, Yoon H, Kasai T, Matsumura A, Atagi S. A High PD-L1 Expression in Pulmonary Pleomorphic Carcinoma Correlates with Parietal-pleural Invasion and Might Predict a Poor Prognosis. Intern Med 2019;58:921-927.
  5. Takeda M, Kasai T, Naito M, Tamiya A, Taniguchi Y, Saijo N, Naoki Y, Okishio K, Shimizu S, Kojima K, Nagoya A, Sakamoto T, Utsumi T, Yoon H, Matsumura A, Atagi S. Programmed Death-ligand 1 Expression With Clone 22C3 in Non-small Cell Lung Cancer: A Single Institution Experience. Clin Med Insights Oncol 2019;13:1179554918821314.

和文

  1. 澤　兼士，川口知哉．副作用予測因子の現状と期待．呼吸器内科 2019;35:505-509.
  2. 金田裕靖．話題のくすり ロルラチニブ．日本病院薬剤師会雑誌 2019;55:1096-1099.
  3. 澤　兼士、金田裕靖．NGT-腎機能での用量調節が必要-．倉田宝保，吉岡弘鎮，金田俊彦編．肺がん化学療法 副作用マネジメント プロのコツ．東京：メジカルビュー社．2019 pp. 158-160.
  4. 金田裕靖．治療の概要 Q29-Q31．日本肺癌学会編．患者さんのための肺がんガイドブック 2019年版 悪性胸膜中皮腫・胸腺腫瘍含む．東京：金原出版．2019;73-76.